Potential of using cerium oxide nanoparticles for protecting healthy tissue during accelerated partial breast irradiation (APBI).

Autor: Ouyang Z; University of Massachusetts Lowell, Lowell, MA, USA. Electronic address: Zi_Ouyang@student.uml.edu., Mainali MK; University of Massachusetts Boston, Boston, MA, USA., Sinha N; Wentworth Institute of Technology, Boston, MA, USA., Strack G; University of Massachusetts Lowell, Lowell, MA, USA., Altundal Y; University of Massachusetts Lowell, Lowell, MA, USA., Hao Y; University of Massachusetts Lowell, Lowell, MA, USA., Winningham TA; Space Coast Cancer Center, Titusville, FL, USA., Sajo E; University of Massachusetts Lowell, Lowell, MA, USA., Celli J; University of Massachusetts Boston, Boston, MA, USA., Ngwa W; University of Massachusetts Lowell, Lowell, MA, USA; Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) [Phys Med] 2016 Apr; Vol. 32 (4), pp. 631-5. Date of Electronic Publication: 2016 Apr 01.
DOI: 10.1016/j.ejmp.2016.03.014
Abstrakt: The purpose of this study is to investigate the feasibility of using cerium oxide nanoparticles (CONPs) as radical scavengers during accelerated partial breast irradiation (APBI) to protect normal tissue. We hypothesize that CONPs can be slowly released from the routinely used APBI balloon applicators-via a degradable coating-and protect the normal tissue on the border of the lumpectomy cavity over the duration of APBI. To assess the feasibility of this approach, we analytically calculated the initial concentration of CONPs required to protect normal breast tissue from reactive oxygen species (ROS) and the time required for the particles to diffuse to various distances from the lumpectomy wall. Given that cerium has a high atomic number, we took into account the possible inadvertent dose enhancement that could occur due to the photoelectric interactions with radiotherapy photons. To protect against a typical MammoSite treatment fraction of 3.4Gy, 5ng·g(-1) of CONPs is required to scavenge hydroxyl radicals and hydrogen peroxide. Using 2nm sized NPs, with an initial concentration of 1mg·g(-1), we found that 2-10days of diffusion is required to obtain desired concentrations of CONPs in regions 1-2cm away from the lumpectomy wall. The resultant dose enhancement factor (DEF) is less than 1.01 under such conditions. Our results predict that CONPs can be employed for radioprotection during APBI using a new design in which balloon applicators are coated with the NPs for sustained/controlled in-situ release from within the lumpectomy cavity.
(Copyright © 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: